Brain AI-Assisted Diagnosis Solution Market Report 2026

The brain artificial intelligence (AI)-assisted diagnosis solution market size has grown exponentially in recent years. It will grow from $2.19 billion in 2025 to $2.76 billion in 2026 at a compound annual growth rate (CAGR) of 25.8%. The growth in the historic period can be attributed to growth in medical imaging volumes, rising prevalence of neurological disorders, increasing reliance on radiology diagnostics, early adoption of AI-assisted clinical tools, improvements in imaging resolution.

The brain artificial intelligence (AI)-assisted diagnosis solution market size is expected to see exponential growth in the next few years. It will grow to $6.84 billion in 2030 at a compound annual growth rate (CAGR) of 25.5%. The growth in the forecast period can be attributed to increasing demand for early and accurate neurological diagnosis, rising investments in AI healthcare solutions, expansion of cloud-based medical platforms, growing regulatory approvals for AI diagnostics, increased integration of AI into clinical workflows. Major trends in the forecast period include increasing adoption of AI-based brain imaging analysis, rising use of deep learning algorithms in neurology, growing integration of clinical decision support systems, expansion of cloud-based diagnostic platforms, enhanced focus on early disease detection.

The rising prevalence of neurological disorders is expected to drive the growth of the brain artificial intelligence (AI)-assisted diagnosis solution market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, and nerves, resulting in cognitive, motor, and sensory impairments. This increase is largely associated with the aging global population, as aging gradually impairs neuronal function, reduces brain plasticity, and increases oxidative stress, contributing to the onset and progression of such conditions. Brain AI-assisted diagnosis solutions support neurological disorder management by providing rapid, accurate, and objective analysis of brain imaging or electrical activity. They improve clinical decision-making, enable early detection of conditions such as stroke, concussion, and Alzheimer’s disease, and facilitate personalized treatment planning. For example, in July 2024, the National Health Service (UK) reported 487,432 patients diagnosed with dementia - a progressive brain disorder affecting memory, thinking, and daily activities - by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. The growing prevalence of neurological disorders is therefore boosting the demand for brain AI-assisted diagnosis solutions.

Leading companies in the brain AI-assisted diagnosis solution market are focusing on developing advanced technologies, such as deep learning platforms, to improve diagnostic accuracy, real-time analysis, and clinical decision-making. Deep learning platforms leverage neural networks and data analytics to analyze brain imaging or electrical activity, detect subtle abnormalities, and provide actionable insights for clinicians. For instance, in June 2025, BrainScope Company Inc., a US-based neurotechnology company, launched a next-generation deep learning platform featuring a Large Neural Model (LNM). This platform applies techniques similar to large language models (LLMs) to electroencephalogram (EEG) data, enabling automated analysis without specialized quantitative EEG (qEEG) interpretation. It supports a range of brain health conditions, including concussion, stroke, and early Alzheimer’s detection, by delivering rapid, objective, and clinically actionable insights. The platform also aids in developing refined biomarkers for precision-driven clinical trial recruitment, early diagnosis, and personalized treatment.

In January 2025, SyntheticMR AB, a Sweden-based healthcare company, acquired Combinostics Oy for $5.03 million (€4.3 million). Through this acquisition, SyntheticMR aims to expand its portfolio of AI-driven neuroimaging solutions by integrating Combinostics’ cNeuro platform, enhancing its brain diagnostic capabilities and strengthening its presence in the European healthcare market. Combinostics Oy is a Finland-based diagnostic company specializing in AI-assisted brain diagnosis solutions.

Major companies operating in the brain artificial intelligence (AI)-assisted diagnosis solution market are Viz.ai Inc., Aidoc Medical Ltd., RapidAI Inc., Qure.ai Technologies Pvt. Ltd., Ceribell Inc., Infervision Inc., Quibim S.L., Brainomix Ltd., Hyperfine Inc., QMENTA Inc., BrainScope Company Inc., BioMind Inc., Cortechs.ai Inc., Heuron Inc., Zeto Inc., icometrix NV, Cercare Medical AB, VUNO Inc., NeuraSignal Inc., Aikenist Inc., Avicenna.AI Inc., BrainKey Technologies Inc., Deepwise AI Co. Ltd.

North America was the largest region in the brain artificial intelligence (AI)-assisted diagnosis solution market in 2025. The regions covered in the brain artificial intelligence (AI)-assisted diagnosis solution market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain artificial intelligence (AI)-assisted diagnosis solution market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the brain AI-assisted diagnosis solution market by increasing costs of imported AI-optimized processors, imaging hardware, data storage systems, and networking equipment used in advanced diagnostic platforms. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported high-performance computing components, while Asia-Pacific faces cost pressures on AI software deployment infrastructure. These tariffs are raising implementation costs and extending adoption timelines. However, they are also encouraging local development of AI software, regional data infrastructure investments, and domestic manufacturing of diagnostic hardware to support long-term market growth.

The brain artificial intelligence (AI)-assisted diagnosis solution market research report is one of a series of new reports that provides brain artificial intelligence (AI)-assisted diagnosis solution market statistics, including brain artificial intelligence (AI)-assisted diagnosis solution industry global market size, regional shares, competitors with a brain artificial intelligence (AI)-assisted diagnosis solution market share, detailed brain artificial intelligence (AI)-assisted diagnosis solution market segments, market trends and opportunities, and any further data you may need to thrive in the brain artificial intelligence (AI)-assisted diagnosis solution industry. This brain artificial intelligence (AI)-assisted diagnosis solution market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain artificial intelligence (AI)-assisted diagnosis solutions are software-driven systems that use AI algorithms to analyze brain imaging and clinical data for detecting neurological disorders. Their primary goal is to support clinicians in the early and accurate diagnosis of conditions such as stroke, tumors, and neurodegenerative diseases, enhancing decision-making, treatment planning, and patient outcomes. These solutions improve diagnostic efficiency by reducing manual interpretation time and minimizing errors.

The main product types of brain AI-assisted diagnosis solutions include hardware, software, and services. Hardware comprises the physical devices and equipment used to capture, process, and analyze neurological data, which AI algorithms then interpret to aid brain diagnosis. These solutions leverage technologies such as computer vision, deep learning, machine learning, and natural language processing and can be deployed via cloud or on-premises modes. Applications include disease detection, patient monitoring, radiology analysis, and surgical robotics assistance, serving a range of end users such as hospitals, clinics, diagnostic centers, and research institutes.

The brain artificial intelligence (AI)-assisted diagnosis solution market consists of revenues earned by entities by providing services such as clinical decision support, artificial intelligence (AI)-powered brain imaging analysis, predictive analytics for disease progression, and remote diagnostics and tele-neurology. The market value includes the value of related goods sold by the service provider or included within the service offering. The brain artificial intelligence (AI)-assisted diagnosis solution market also includes sales of neuroinformatics platforms, artificial intelligence (AI)-enabled imaging devices, cloud-based analytics solutions, and artificial intelligence (AI)-integrated medical imaging hardware. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.